A Case-control Study on the Differentiation Between Cough Variant Asthma and Chronic Cough
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Hangzhou, China
- The First Affiliated Hospital of Zhejiang Chinese Medical University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- (1) age from 18 years old to 65 years old; (2) clinical diagnosis of CVA and CC .
Exclusion Criteria:
- Exclusion criteria for CVA were: a history of COPD, bronchiectasis, bronchitis, cystic fibrosisor pneumonia, interstitial lung disease, pulmonary tuberculosis, lung cancer; cough caused by drugs or treatments; patients with upper airway cough syndromes (UACS) and gastroesophageal reflux-related cough (GERC) or other apparent causes of cough; patients who used corticosteroid (ICS) in the previous four weeks; Exclusion criteria for CC were: a history of variable airway limitation.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
cough variant asthma
(1) chronic cough (≥8 weeks) as the sore or predominant symptom; (2) variable airway limitation evaluated by BHR test; (3) a positive response to anti-asthma therapy; (4) No other causes of chronic cough.
|
Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation.
This test was stopped until a reducing in baseline FEV1 of 20%.
|
|
chronic cough
(1) chronic cough (≥8 weeks) as the sore or predominant symptom; (2) without radiographic evidence of lung disease; (3) with no fever, blood-stained sputum or other active respiratory injection;
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
positive bronchial provocation test
Time Frame: up to 1 week
|
Patients were asked to inhale gradually increasing doses of methacholine (0.9% saline, 0.078, 0.312, 1.125 and 2.504 mg), and FEV1 was measured after each inhalation.
This test was stopped until a reducing in baseline FEV1 of 20%
|
up to 1 week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
small airway dysfuction
Time Frame: up to 1 week
|
MMEF% pred, FEF50% pred, FEF75% pred
|
up to 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Junchao Yang, Dr, The First Affiliated Hospital of Zhejiang Chinese Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2023-KLS-100-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
NCT07412769RecruitingAsthma in Children | Asthma Acute | Asthma Crisis | Asthma Childhood
-
NCT07629830Not yet recruitingAsthma Attack | Asthma Acute
-
NCT07261423RecruitingAsthma Exacerbation | Childhood Asthma | Air Pollution, Risk Reduction Behaviors | Asthma Control
-
NCT03277170WithdrawnAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; Status
-
NCT07582211Not yet recruitingAcute Asthma | Pediatric Asthma | Non-invasive Positive Pressure Ventilation | BiPAP
-
NCT03642418CompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
NCT06377345RecruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
Clinical Trials on positive bronchial provocation test
-
NCT03696602CompletedChildhood Asthma
-
NCT00519740CompletedHypersensitivity | Allergy | Bronchial Hyperreactivity | Bronchial Asthma
-
NCT04668027RecruitingChronic Airway Disease
-
NCT02399579Completed
-
NCT04437355CompletedAnkle Fracture - Lateral Malleolus | Ankle Fracture, Trimalleolar | Ankle Fracture, Bimalleolar
-
NCT04352088RecruitingAllergic Rhinitis | Allergic Asthma
-
NCT05100290Completed
-
NCT02271620CompletedOther Allergic Rhinitis
-
NCT03459456Active, not recruitingObsessive-Compulsive Disorder | OCD